Astellas has become an active player in gene therapy. MedCity News caught up with company executive Richard Wilson, who explained Astellas’s strategy, the clinical holds on its two most advanced programs, and the rationale behind its recent gene therapy deals.
Astellas has purchased an equity stake in Taysha Gene Therapies in a $50 million deal that gives it an option to license the company’s two lead gene therapy candidates. The Japanese pharmaceutical giant also gains the option to buy its new partner outright depending on clinical and regulatory developments expected in the coming year.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
Astellas is on the lookout for new, early stage drugs to boost its pipeline - particularly because later-stage assets still have overinflated valuations.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Medtronic highlighted a shift in its diabetes strategy towards smaller deals in the latest quarterly earnings report.
LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undiscl...